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Summary
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb)
capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment
which will be too expensive to be accessible by the most important target population, the poor in
under-developed regions such as sub-Saharan Africa. Here, we report the expression of VRC01
in plants as an economic alternative to conventional mammalian-cell-based production
platforms. The heavy and light chain genes of VRC01 were cloned onto a single vector, pTRAk.2,
which was transformed into Nicotiana benthamiana or Nicotiana tabacum using transient and
stable expression production systems respectively. VRC01 has been successfully expressed
transiently in plants with expression level of approximately 80 mg antibody/kg; stable transgenic
lines expressing up to 100 mg antibody/kg were also obtained. Plant-produced VRC01 from
both systems showed a largely homogeneous N-glycosylation profile with a single dominant
glycoform. The binding kinetics to gp120 IIIB (approximately 1 nM), neutralization of HIV-1 BaL or
a panel of 10 VRC01-sensitive HIV-1 Env pseudoviruses of VRC01 produced in transient and
stable plants were also consistent with VRC01 from HEK cells.
Introduction
Human immunodeficiency virus infection/acquired immunodefi-
ciency syndrome (HIV/AIDS) is a global pandemic and one of the
leading causes of deaths in the world (WHO, 2008). The worst
affected region is sub-Saharan Africa, accounting for nearly 70
per cent of all people living with HIV. There is currently no cure or
effective vaccine for HIV/AIDS. Current treatment protocols
involve antiretroviral therapy (ART), a combination of three or
more antiretroviral (ARV) drugs which control viraemia, thus
increasing the survival rate of HIV-infected individuals (May and
Ingle, 2011). ARV drugs can also be used to reduce the chance of
HIV transmission through ‘treatment as prevention’ (TasP) (WHO,
2012a). Otherwise, ART can be used by noninfected individuals
topically as vaginal or rectal microbicides (Shattock and Rosen-
berg, 2012) or as pre- or postexposure prophylaxis (PrEP or PEP)
(WHO, 2012b; WHO and ILO, 2007).
Life-long treatment or prevention using ARV drugs is expen-
sive, between US$10 000 and US$12 000 per year per person in
the USA (Bartlett, 2006) as it involves sustained periods of drug
delivery. Worldwide treatment coverage of people requiring
access to ART, currently at 54 per cent (UNAIDS, 2012), still falls
below the target goal of 80 per cent (UN, 2011; WHO, UNAIDS
and UNICEF, 2007). Moreover, long-term use of ARV drugs can
also result in toxicities with unpredictable effects on health as well
as development of drug resistance and viral rebound if the
treatment regimen is not adhered to (Barbaro, 2006; Barbaro
et al., 2005; Chen et al., 2013; Rusconi et al., 2007). Therefore,
the search continues for additional therapeutic modalities to
complement or replace current ARV drugs (Arts and Hazuda,
2012).
Broadly neutralizing antibodies (bNAb) constitute a rare class of
antibodies which are effective against a broad range of HIV strains
(Doria-Rose et al., 2010; Li et al., 2007, 2009; Simek et al., 2009).
They naturally develop in 15%–25% of individuals after many
years of infection. Most of the neutralizing antibodies, including
bNAbs, disrupt viral replication by immune exclusion but there are
also evidence to suggest viral neutralization by Fc-mediated
antibody activities (Overbaugh and Morris, 2012). Since 2009, a
new generation of bNAbs, which are more potent and broadly
neutralizing compared with previous HIV-1 mAbs, has been
identified (see Chen et al., 2013 for review). This new generation
of bNAbs holds much promise for HIV-1 therapy and prevention.
Recently, Klein et al. (2012) has shown that a combination of five
new-generation bNAbs can effectively control HIV-1 infection and
suppress viral load to levels below detection in a humanized mice
model. The antibody cocktail has longer half-life compared with
current ARV drugs and can control viraemia for an average of
60 days after therapy was discontinued. There are also plans for a
clinical trial to test the new-generation bNAbs to prevent the
spread of HIV-1 in high-risk adult males (Wadman, 2013).
VRC01, one of these new generation broadly neutralizing
IgG1, was obtained through the use of resurfaced antigenic
probes to select for B cells (obtained from a HIV-1 infected donor)
that express bNAbs directed at HIV-1 CD4 binding sites (Wu
et al., 2010). It blocks viral entry by partially mimicking the
interaction of the CD4 receptor with HIV-1 gp120 envelope
glycoprotein (Zhou et al., 2010). In vitro neutralization tests have
shown that VRC01 is capable of neutralizing 91% of known HIV-
1 isolates (Wu et al., 2010). The antibody, when applied as a
topical gel, also protected against HIV-1 infection in vaginally
challenged humanized mice (Veselinovic et al., 2012). Moreover,
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in the preclinical testing conducted in nonhuman primates,
preliminary results showed that animals receiving VRC01 were
protected against mucosal challenge with a chimeric simian-
human immunodeficiency virus (SHIV) compared with the control
group (Pegu et al., 2011).
An investigational new drug application to the US Food and
Drug Administration is currently underway for VRC01 (Lopez
et al., 2013). The investigators proposed that VRC01 will be first
safety-tested in adults and infants in the USA. It was then hoped
that subsequent trials will be carried out in African countries such
as Malawi, Tanzania and Uganda to investigate VRC01 as a
prophylactic to complement ART in the prevention of mother-to-
child transmission of HIV-1 via breastfeeding. The proposal for the
clinical trial raised issues about testing a treatment which would
not be affordable to its target population in low-income
countries, as monoclonal antibody therapies are usually very
expensive (Lopez et al., 2013; Wadman, 2013).
Plants offer an attractive alternative to conventional mamma-
lian-cell-culture-based platforms for recombinant protein produc-
tion, including monoclonal antibodies. In recent years, technology
developments have resolved early difficulties with expression
levels (Fischer et al., 2012). Furthermore, industry and regulatory
concerns regarding cGMP compliant manufacture for human use
have been addressed, with regulatory approvals for clinical trials
in the UK (J. Ma, pers. comm.) and the USA (J. Butler, pers.
comm.). Here, we compare transient and stable transgenic plant
production platforms to manufacture new-generation bNAbs
against HIV-1, using VRC01 as an example. VRC01 light and
heavy chain genes were cloned into a single vector and
transformed into tobacco plants. We report the successful
production of VRC01 in tobacco using both methods. The
plant-produced VRC01 antibodies possess a largely homogenous
glycosylation pattern, and we have also investigated their binding
kinetics. Furthermore, VRC01 from transiently and stably trans-
formed plants neutralizes HIV-1 isolates across four different
clades with neutralizing breadth and potency consistent with
VRC01 from HEK cells. These developments now offer hope that
the specific advantages of plant production platforms—namely
low manufacturing entry cost, large scalability and simple
technology amendable to transfer to developing countries—
may soon be realized.
Results
Determination of antibody accumulation levels
Plant-codon-optimized VRC01 light and heavy chain genes
(GeneArt) were cloned into the binary expression vector pTRAk.2
(van Dollerweerd, C.J., Teh, A.Y-H., Banyard, A.C., Both, L.,
Lotter-Stark, H.C.T., Tsekoa, T., Phahladira, B., Shumba, W.,
Sabeta, C.T., Szeto, T.H., Gruber, C., Fooks, A.R., Chikwamba,
R.K. and Ma, J.K-C., in preparation).
For transient expression, Agrobacterium harbouring the T-DNA
constructs were delivered into Nicotiana benthamiana via vacuum
infiltration (Kapila et al., 1997). Twelve individual plants
were used. The expression levels of 6-day postinfiltrated (dpi)
N. benthamiana leaves (approx. 5–7 g) from each plant were
determined using an ELISA designed to detect fully assembled IgG.
The experiment was performed twice. The average expression level
was 81 mg/kg fresh weight VRC01 mAb before purification.
pTRAk.2-VRC01 was also used to generate stably transformed
plants through Agrobacterium co-cultivation of Nicotiana taba-
cum cv. Petit Havana SR-1 leaf discs (Horsch et al., 1985). Thirty-
five primary transformants (T0) were tested using ELISA set up to
detect only full-length IgGs. The highest producing expressed at
~100 mg/kg fresh weight (data not shown). This T0 plant line was
self-fertilized to generate T1 plants. 30 T1 plants were screened and
the expression levels averaged about 130 mg/kg (unpurified;
Table 1). The yield (before purification) of the VRC01 obtained
from the stably transformed T1 generationwas not significantly dif-
ferent (P < 0.05) from the expression levels from N. benthamiana
plants transiently transformed with pTRAk.2 (Table 1).
PAGE and Western blot analysis of mAb integrity
Coomassie-stained SDS-PAGE gels of VRC01 purified from
transient and transgenic plants are shown in Figure 1a. In both
cases, there is a major band at ~150 kDa in the nonreduced
samples that corresponds to the full-length IgG band identified in
the positive control human IgG sample (top arrow). The identity
of this band was confirmed by Western blot, as it was detected by
both antiheavy and light chain antisera (Figure 1b, d). In all these
antibody samples (transient, stable and positive IgG control),
there were numerous smaller bands, which are likely to be
degradation products as they were also immunoreactive in the
Western blot. The stably expressed VRC01 appeared to demon-
strate slightly more degradation, with prominent bands at
~100 kDa and ~50 kDa. Both of these bands were reactive with
the antilight chain reagent in Western blot (Figure 1d). Under
reducing conditions, the bands resolved into a ~50-kDa band and
a ~25-kDa band (Figure 1a). Identical bands were observed for
the HEK-cells-derived version of VRC01. These bands were
identified as heavy and light chains by Western blotting
(Figure 1c, e).
Glycopeptide analysis
The analysis of heavy and light chain sequences of VRC01 using
EssembleGly (Caragea et al., 2007) revealed two potential
N-linked glycosylation sites: one in the heavy chain CH2 region
at N297 and one in the FR3 of the light chain VL region (Figure 2a).
Glycan addition at both sites in VRC01 derived from HEK cells,
transient plants and transgenic plants were confirmed using liquid
chromatography-electrospray ionization-mass spectrometry
(LC-ESI-MS) after S-carbamidomethylation and trypsin/GluC
digest (Figure 2b–d). The deconvoluted spectra of the glycopep-
tide elution range were used for identification of N-glycan
structures. HEK-cells-derived VRC01 was shown to have
GnGnF6 as the predominant glycan structure on the heavy
chain, with lesser amounts of GnAF6, AAF6 and GnGnF6bi
structures (Figure 2b, upper panel, nomenclature as used at
www.proglycan.com). On the light chain, there was greater
diversity of glycans with at least ten structures identified
(Figure 2b, lower panel).
Table 1 Expression levels (before purification) of VRC01 in transient
(n = 24) and stable (n = 30) expression systems. Results are expressed
as mean  SD (in mg/kg fresh weight)
Vector Host
Production
system Yields (mg/kg)
pTRAk.2 N. benthamiana Transient 81  17 (n = 24)
pTRAk.2 N. tabacum
cv. Petit Havana SR-1
Stable 129  76 (n = 30*)
*T1 generation from self-crossed primary transformant.
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In contrast, the plant versions of VRC01 (which were similar),
both have GnGnXF3 as the major glycan structure, with MGnXF3
and MMXF3 as the two other major glycans (Figure 2c, d). This
was observed in both the heavy and light chains. For the light
chain, the MMXF3 glycan was slightly more prevalent in stable
expression of the antibody (Figure 2d, lower panel).
HIV-gp120 binding kinetics
To evaluate the antigen-binding kinetics of plant-produced
VRC01, binding of HIV-1 envelope glycoprotein gp120 IIIB to
VRC01 mAb captured on a protein A-coated CM5 sensor chip
was measured by surface plasmon resonance (SPR). A preliminary
direct ELISA confirmed that plant-derived VRC01 mAb binds to
gp120 (data not shown). Protein A was first immobilized onto a
CM5 sensor ship by amine coupling. Then, plant- or HEK-cells-
derived VRC01 was captured on to the chip surface. Purified
recombinant gp120 was injected over the chip at 20 lg/mL. The
binding response of VRC01 from transient and stable plants as
well as from HEK cells to gp120 molecules was fitted with a 1 : 1
Langmuir model after subtraction of the response from the blank
flow cell and protein A-antibody only controls (Figure 3a). The
equilibrium dissociation constant (KD) of the interaction between
plant VRC01 and gp120 was calculated to be 1.68  0.37 and
1.39  0.62 nM, respectively, for transient and stable plant-
derived VRC01 compared with 0.66  0.05 nM from VRC01
from HEK cells (Figure 3b). The association and dissociation
constants of the SPR analyses are also shown in Figure 3b.
There were no significant differences between the results
(P < 0.05). Furthermore, there were no differences in relative
antigen-binding activity (rela) between the two plant-derived
VRC01 and HEK-cells-derived VRC01.
TZM-bl-neutralizing assays
We initially performed HIV neutralization assays comparing
VRC01 produced in transient and stable plants and in HEK
cells in inhibiting TZM-bl cell infection by HIV-1 BaL. The
antibodies were first incubated with HIV-1 BaL at a range of
concentrations before being added to TZM-bl cells containing
(a)
(b)
(d) (e)
(c)
Figure 1 Expression profiles of VRC01 produced
in plants and HEK cells. (a) Coomassie-stained
SDS-PAGE gel showing VRC01 purified from
transient plants (left panel) and stable
transformants (T0 generation; middle panel) under
nonreducing (NR) and reducing (R) conditions.
Commercially available human IgG1 kappa from
human serum (Sigma) was used as positive control
(right panel). Five micrograms of purified protein
was loaded onto each lane. Full-length IgGs on
nonreducing gels, as well as the heavy and light
chain on reducing gels, are indicated by black
arrows. (b–e) Nonreducing (b and d) and reducing
(c and e) Western blot analysis of VRC01 in 1)
transient plant crude extract, 2) crude extract
from stable transformants (T0 generation) and 3)
VRC01 purified from HEK cells. The heavy chain
was detected using a polyclonal goat anti-human
IgG (Fc fragment) antiserum (b and c), and the
light chain was detected using a goat anti-human
IgG kappa chain antibody (d and e). Full-length
IgG, as well as heavy and light chains, are
indicated by black arrows.
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the HIV Tat-regulated luciferase reporter gene. Virus neutral-
ization by the antibodies was measured as a function of a
reduction in the expression of the luciferase reporter gene.
VRC01 mAbs from plants and HEK cells showed similar
neutralizing activity (Figure 4a), with IC50 of 0.339, 0.407
and 0.319 lg/mL for VRC01 from transient plants, stable
plants and HEK cells, respectively (Figure 4b). The IC50 values
of plant- and HEK-cells-derived VRC01 were not statistically
different (P < 0.05).
A more comprehensive analysis using a variety of HIV-1 clades
and isolates was then performed (courtesy of Dr. M. Seaman,
through the CAVD). 10 VRC01-sensitive pseudoviruses from
(a)
(b)
Figure 2 Characterization of N-glycan population of VRC01 from HEK cells, transient plants and transgenic plants. (a) Amino acid sequence of VRC01
heavy (above) and light chain (below). The highlighted portion represents the glycopeptide fragment generated after trypsin/GluC digest and subsequently
analysed using LC-ESI-MS. Potential N-glycosylation sites are underlined: the heavy chain has an Asn/Ser/Thr consensus sequence in the CH2 region; the
light chain has an Asn/Leu/Thr consensus sequence in the FR3 of VL region. (b, c and d) Deconvoluted glycopeptide spectra of VRC01 derived from
(b) HEK cells, (c) transiently transformed Nicotiana benthamiana plants and (d) transgenic Nicotiana tabacum plants as determined by LC-ESI-MS after
S-carbamidomethylation and trypsin/GluC digest. The glycopeptides analysed were EEQYNSTYR (1189.51 Da) in the heavy chain (top panel) and
WGPDYNLTISNLE (1521.72 Da) in the light chain (bottom panel; glycosylation sites are underlined). Marked peaks correspond to glycans with different m/z
values. Diamonds, white circles, dark squares, grey circles, triangles and stars represent N-acetylneuraminic acid, galactose, N-acetylglucosamine, mannose,
fucose and xylose, respectively.
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(d)
(c)
Figure 2 Continued
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clades A, B, C and G were tested (Figure 4b). The IC50 titres of
VRC01 from transient plants were concordant with the HEK-cells-
produced VRC01 mAb. VRC01 from stable plants also neutralized
all pseudoviruses, but appeared to be slightly less potent.
Discussion
Broadly neutralizing antibodies (bNAbs) have different properties
compared with small molecule antiretroviral (ARV) drugs and
represent an opportunity for alternative or complementary
prophylactic and therapeutic approaches. For example, they are
highly specific, interact and neutralize the pathogen directly and
also possess a longer half-life in vivo (Klein et al., 2012). Anti-HIV
bNAbs can be used in conjunction with small molecule ARV drugs
in a multidrug combination, similar to antitumour (Scott et al.,
2012) or antimicrobial (Pachl et al., 2006) combined therapy, to
counter drug-resistant HIV-1 strains and viral escape (Pirrone
et al., 2011). Furthermore, they can also be used for individuals
intolerant to current ARV drugs. However, biologics are costly.
The top 15 mAbs and Fc fusion products cost ~$8 000 per gram
in 2008 (Kelley, 2009). Prophylactic possibilities include vaginal or
rectal microbicides, pre-exposure prophylaxis (PrEP), postexposure
prophylaxis (PEP) and perinatal intervention. Furthermore, if mAbs
are to be used in antiretroviral applications, several antibodies
might be needed in combination as an antibody cocktail.
Considering the long-term, sustained usage of ARV drugs in the
treatment and prevention of HIV/AIDS (WHO, 2006), it is
therefore imperative to look for less expensive and more scalable
production platforms which can be used to replace or supplement
current mammalian-cell-culture-based systems (Beck et al.,
2010).
Plants were first proposed as a manufacturing platform for
monoclonal antibodies over 20 years ago (Hiatt et al., 1989).
Initial optimism for low-cost high-volume production was blunted
both by technical limitations of the early technology as well as
doubts over public acceptability of the new biotechnology. In
(a)
(b)
Figure 3 Binding kinetics of VRC01 from plant and HEK cells to HIV gp120 IIIB. (a) SPR sensorgram comparing the interaction of Protein-A captured
VRC01 from transient plants (VRC01 transient), stably transformed plants (VRC01 stable) and HEK cells (VRC01 HEK) with recombinant gp120 III. Protein A
was immobilized on a CM5 chip, and VRC01 antibodies were captured to 100RU. gp120 were injected at a concentration of 20 lg/mL. Experimental
curves are shown as grey lines and fitted curves shown in black. Sensorgram shown represents one of three similar experiments. (b) Binding kinetics:
association constant (Ka), dissociation constant (Kd) and affinity (KD) are shown for VRC01 from three sources. Each assay was performed in triplicate. Error
bars denotes  SD.
(a)
(b)
Figure 4 Neutralization of HIV-1 virus and pseudoviruses by VRC01
produced in plants and HEK cells. (a) Neutralization curves of transient
plant- ( ), stable transgenic plant -( ) and HEK cells -( )produced
VRC01 against HIV-1BaL; tested using TZM-bl cells. A nonspecific plant-
derived antibody was used as negative control ( ). Error bars denotes 
SD. Each assay was repeated three times. (b) Neutralization IC50 values
(lg/mL) of VRC01 produced in transient and stable transgenic plants as
well as HEK cells against HIV-1 BaL (clade B) and 10 VRC01-sensitive
HIV-1 Env pseudoviruses from clade A, B, C and G; tested using TZM-bl
cells.
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addition, acceptance by the industry was affected by widespread
concerns over the pharmaceutical regulatory compliance by
plant-based manufacturing systems. The technical issues of
recombinant protein expression levels have been addressed
through a variety of means (Desai et al., 2010), including gene
codon optimization (Batard et al., 2000; Rouwendal et al., 1997),
expression vector design (Gleba et al., 2007; Sainsbury et al.,
2009, 2010), improved screening strategies of potential produc-
tion lines, optimizing plant cultivation (Colgan et al., 2010) and
plant breeding (Hood et al., 2002).
In 2012, the first plant-derived pharmaceutical product,
ElelysoTM by Protalix BioTherapeutics, was approved by the FDA
to treat Type I Gaucher’s disease (Edney, 2013). Regulatory
approvals have also been granted for clinical trials of, among
others, recombinant human insulin produced in transgenic
safflower, non-Hodgkins’ lymphoma vaccine (comprising of
monoclonal antibodies possessing the B-cell lymphoma idiotype)
expressed transiently in N. benthamiana, and in 2011, the anti-
HIV monoclonal antibody 2G12 produced in transgenic N. taba-
cum (Ma, J.K-C., Drossard, J., Lewis, D., Altmann, F., Boyle, J.,
Christou, P., Cole, T., Dale, P., van Dolleweerd, C.J., Isitt, V.,
Katinger, D., Lobedan, M., Mertens, H., Paul, M.J., Rademacher,
T., Sack, M., Sparrow, P., Stiegler, G., Stoger, E., Twyman, R.M.,
Vcelar B. and Fischer R., pers. comm.). It is thus evident that
recombinant pharmaceuticals manufacturing in plants are feasi-
ble. The focus now shifts back to target products and applications
where plant manufacture is most desirable. Although lower cost
of goods is a desirable feature of Nicotiana-based manufacturing,
the potential for low cost of entry to clinical trials (a result of
reduced early capital costs) may be an additional and significant
driver. Of equal importance is the potential scalability of
manufacture, which opens up prophylactic and/or therapeutic
interventions that were previously unattainable.
HIV-neutralizing antibodies are therefore an obvious target for
manufacture in plants. They would almost certainly be required at
a very large scale, and cost of goods may become an important
consideration for cocktail products containing two, three or more
active drug products. Very recently, two groups reported
production of VRC01 mAb in plant transient expression systems
(Hamorsky et al., 2013; Rosenberg et al., 2013). Hamorsky et al.
(2013) devised a novel tobamovirus replicon vector in N. benth-
amiana, while Rosenberg et al. (2013) reported transient expres-
sion using the same pTRAk vector used here in both
N. benthamiana and N. tabacum. Both groups demonstrated
successful expression of functional VRC01 of levels equivalent to
those achieved here. In this study, we have demonstrated VRC01
production by stable expression in transgenic plants.
The finding that the expression levels in stable transgenics and
transient expressionwere quite similarwas unexpected, as previous
literature has generally indicated much higher levels of expression
using transient systems (Marillonnet et al., 2005; Sainsbury and
Lomonossoff, 2008). Interestingly, with a second transient expres-
sion system CPMV-HT (Sainsbury and Lomonossoff, 2008), similar
levels of expression were also obtained (data not shown). In the
case of HIV bNAbs, the use of a highly efficient transgenic system
may be extremely advantageous, because the simplified manufac-
turing process could be performed in resource-poor regions,
especially those that have an urgent interest in addressing HIV
transmission.
The transgenic plant lines generated here expressed VRC01
with no additional sequences (such as the KDEL tags used by
Rosenberg et al.) or residual amino acids (as left by the kex2p-like
cleavage strategy used by Hamorsky et al.). These transgenic
plant lines have now entered a breeding programme to achieve
homozygosity and establish genetic and phenotypic stability,
which is the initial requirement for developing a master seed
bank, leading eventually to GMP compliance (EMEA, 2008).
VRC01 has two potential N-glycosylation sites in the heavy
chain hinge region and Framework 2 of the light chain.
Glycoanalysis of HEK-cells-derived VRC01 has not been published
and this is the first report of VRC01 glycosylation in plants. We
demonstrated that both potential N-glycosylation sites are
utilized, in all the expression systems. Expression in plants
generally resulted in a less heterogeneous mixture of glycoforms,
as compared with HEK cells, with the typical GnGnXF3 complex
glycan dominant, particularly in transiently expressed VRC01.
Mono-glycosylation of monoclonal antibodies has been demon-
strated for one other antibody produced in plants, the anti-HIV
mAb 2G12 (Forthal et al., 2010; Sainsbury et al., 2010), but not
to our knowledge in other expression systems. In terms of
product quality control, the ability of plants to produce highly
homogeneous drug product could become an important manu-
facturing advantage. In cell-mediated anti-HIV activity, Forthal
et al. (2010) reported that plant-produced 2G12 with the
GnGnXF3 glycoform performed as well as 2G12 produced in
CHO-cells in terms of interaction of the antibody Fc region with
FccRI, FccRIIa and FccRIIb receptors as well as antibody-depen-
dent cell-mediated virus inhibition (ADCVI). 2G12 with plant- or
mammalian-type core fucose did have reduced binding to
FccRIIIa, and its potency in ADCVI assays could be enhanced by
removal of the fucose residue. However, Rosenberg et al. (2013)
showed that the removal of the same core a1,3-fucose from
plant VRC01 did not increase its ADVCI potency. There is no
evidence that plant glycans expressed on mammalian antibodies
are immunogenic in humans. Plant-derived 2G12 with the
GnGnFX3 glycoform was administer vaginally to human volun-
teers with no adverse effects or immunogenicity (Ma, J.K-C.,
Drossard, J., Lewis, D., Altmann, F., Boyle, J., Christou, P., Cole,
T., Dale, P., van Dolleweerd, C.J., Isitt, V., Katinger, D., Lobedan,
M., Mertens, H., Paul, M.J., Rademacher, T., Sack, M., Sparrow,
P., Stiegler, G., Stoger, E., Twyman, R.M., Vcelar B. and Fischer R.,
pers. comm.). That said, it is encouraging to note the advances
that have been made in glycoengineering in plants (Castilho and
Steinkellner, 2012; Castilho et al., 2013; Strasser et al., 2008,
2009) and the potential for producing antibodies with ‘mamma-
lian’ glycans. Interestingly, when mAb 2G12 was expressed with
altered glycosylation, there was no significant increase in
glycoform heterogeneity (Forthal et al., 2010; Strasser et al.,
2008).
The affinity (KD) of VRC01 produced in transient and stable
plants to the HIV-1 envelope glycoprotein gp120 IIIB was 1.68
and 1.39 nM, respectively, as determined by SPR analysis. There
was no significant difference (P < 0.05) in the binding affinities
between plant- and HEK-cells-derived VRC01. Rosenberg et al.
(2013) and Hamorsky et al. (2013) have also compared the
binding of plant- and mammalian-cell-produced VRC01 to gp120
using capture assays with immobilized mouse anti-human IgG or
protein A. Neither group found any difference in the binding
affinities of plant- and mammalian-cell-produced VRC01. Zhou
et al. (2010) obtained a KD of 5.76 nM when they investigated
the binding of HEK-cells-produced VRC01 to 93TH057 gp120
using a direct assay. Furthermore, the gp120 binding activities of
both plant-derived VRC01 were very similar to VRC01 from HEK
cells. This is in contrast to Hamorsky et al. (2013) who reported
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75%–83% relative activity of transiently expressed VRC01 when
compared to HEK-cells-derived VRC01.
Neutralization by plant-derived VRC01 was compared with
HEK-cells-derived VRC01 across 11 HIV-1 virus strains, including
representatives from clades A, B, C and G. The results were
concordant between VRC01 from transient plant and HEK cells,
demonstrating functional equivalence for the plant-derived anti-
body. The IC50 measured in the pseudotype assays suggest a
reduction in potency for VRC01 from stable transformants. This is
not likely to reflect qualitative differences between the VRC01
from various sources. The SDS-PAGE and glycoanalysis suggested
increased proteolytic degradation of the stably produced VRC01
sample. Indeed, this sample had been subjected to at least three
freeze–thaw cycles before pseudotype neutralization analysis
(compared with 1 for the transiently expressed VRC01). No
difference in neutralization of HIV-1 BaL was observed, using
material that had undergone two less freeze–thaw cycle. Thus,
the slight increase in IC50 observed is likely to be due to error in
calculation of the true concentration of full-length, functional IgG
in the tested sample. Degradation of antibody might be
influenced by the expression platform, but no differences were
observed previously when comparing mAb expression by trans-
genic or transient expression (V. Hehle, PhD thesis, University of
London). Edman degradation experiments using three other
human monoclonal antibodies from stably transformed plants
have suggested that the ~100-kDa bands are degradation
products (Hehle et al., 2011; V. Hehle, PhD thesis) likely to
represent (Fab’)2-like fragments. The ~50-kDa band could be light
chain dimers. In fact, light chain excess appears to be required for
maximal expression of intact full-length IgG in plants (Nuttall
et al., 2002). The components of these degradation products
may account for the excess of the 25-kDa band compared with
the 50-kDa band on the reduced PAGE gel (Figure 1a, middle
panel). The results have indicated that further work will be
needed to finalize a downstream purification process and to
characterize the stability in storage of highly purified plant-
derived VRC01. They also highlight the importance of avoiding
repeated freeze–thaw cycles.
In summary, the new-generation bNAb VRC01 was successfully
produced using both stable and transient production platforms.
This was achieved using a single vector that contains both the
light and heavy chain genes under separate promoters. Intact
plant-produced VRC01 was expressed at approximately 80 mg/kg
fresh weight using transient expression platforms, and stable lines
expressing in excess of 100 mg/kg VRC01 were also obtained. In
both cases, the expression levels are significantly higher than that
reported for the 2G12 monoclonal antibody that was advanced
to phase I clinical trial (www.pharma-planta.net). Further work
would be needed to develop appropriate downstream process-
ing/purification protocols, and the efficiency of these protocols
will determine the final productivity of the expression system.
Plant-produced VRC01 showed N-glycosylation profiles that were
similar to HEK-cells-derived VRC01, but more homogeneous.
GnGnXF3 was the single dominant glycan structure. The binding
kinetics of VRC01 produced in stable and transient plants are
consistent with values in the published literature for VRC01 from
HEK cells. Furthermore, the neutralizing breadth and potency of
plant-produced VRC01 matched that of HEK-cells-produced
VRC01 across a panel of HIV-1 virus and pseudoviruses
from four different clades. This was also a first demonstration
of VRC01 production in stably transformed, transgenic lines, a
manufacturing platform which is readily transferable to
resource-poor regions, and for which a regulatory pathway for
cGMP compliant production has already been established in
Europe (EMEA, 2008).
Experimental procedures
Cloning of VRC01 heavy and light chain genes
The heavy (gamma) and light (kappa) chain genes of the broadly
neutralizing antibody VRC01 were plant-codon-optimized using
GeneArt proprietary software (Geneart, Regensburg, Germany)
and provided by MAPP Biopharmaceuticals (San Diego, CA).
For cloning into the binary expression vector pTRAk.2 (Sack
et al., 2007; van Dolleweerd et al., in preparation), the genes
were amplified using the common forward primer 5′
GCGCCCATGGCTAACAAGCACCTGTCT-3′ and the reverse pri-
mer 5′GCGCTCTAGACTAGCACTCTCCCCTATTAAAAG-3′ (for
light chain) or 5′GCGCTCTAGACTACTTACCAGGAGACAGA
GAC-3′ (for heavy chain). Restriction sites used for cloning the
gene in to pTRAk.2 are underlined and the start/stop codons are
in bold. The amplified PCR products were cloned into BsmBI site
(for heavy chain) or BsaI site (for light chain) of a single pTRAk.2
vector using NcoI and XbaI.
Stable transformation of Nicotiana tabacum
Stable transformation of N. tabacum leaf discs was performed as
described by Horsch et al. (1985). Briefly, Agrobacterium
tumefaciens strain GV3101 : pMP90(RK) transformed with
pTRAk.2 harbouring VRC01 light and heavy chain genes was
grown as above. After removal of medium by centrifugation, the
pellet was resuspended in liquid MS (Murashige and Skoog,
1962) medium (Sigma, Gillingham, UK). Leaf discs (1 cm2) of 6-
week-old N. tabacum cv Petit Havana SR-1 grown under sterile
conditions were immersed in the bacterial suspension for 20 min.
The leaf discs were then incubated for 2 days on shoot-inducing
medium (SIM) consisting of MS medium, 0.1 lg/mL a-naphtha-
leneacetic acid (NAA; Sigma) and 1 lg/mL benzylaminopurine
(BAP; Sigma) at 23 °C. The leaf discs were then transferred to SIM
with 500 lg/mL carbenicillin (Apollo Scientific, Stockport, UK) to
eliminate the Agrobacterium and 100 lg/mL kanamycin to select
for transformed cells. Regenerated shoots were rooted on MS
medium with carbenicillin and kanamycin. Rooted plantlets were
transferred to soil. Yields of rooted primary transformants (T0)
were determined by ELISA (see below) of plant crude extracts
obtained from two leaf discs. Three of the highest yielding T0
plants were allowed to self-pollinate to obtain the T1 generation.
The highest yielding T0 plant was also repropagated by tissue
culture to obtain purified VRC01 antibody. Briefly, leaves of the
plant were sterilized for 15 min in 15% sodium hypochlorite.
1-cm2 leaf discs were cultured in SIM with 500 lg/mL carben-
icillin and 100 lg/mL kanamycin. Regenerated shoots were
rooted on MS medium before being transferred to soil. Leaves
of the regenerated plants were harvested for protein purification
after 2.5–3 months just before flowering.
Transient transformation of Nicotiana benthamiana
Vacuum infiltration of N. benthamiana leaves was performed as
described by Kapila et al. (1997). Agrobacterium tumefaciens
strain GV3101 pMP90RK transformed with pTRAk.2 harbouring
VRC01 light and heavy chain genes was grown overnight in Luria-
Bertani (LB) broth, 0.02 mM acetosyringone (Santa Cruz Biotech-
nology, Dallas, TX), 0.01 mM MES (Sigma), 100 lg/mL rifampicin
(Apollo Scientific) and 50 lg/mL kanamycin (Apollo Scientific) at
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28 °C. After removal of the medium by centrifugation, the pellet
was resuspended in infection solution containing 0.1 mM aceto-
syringone, 0.01 mM MES (Sigma) and 0.01 mM MgCl2 (VWR
International, Lutterworth, UK). The final OD600 of the bacterial
suspensions was adjusted to 0.3. Fully expanded leaves of 3.5-
week-old N. benthamiana plants were immersed in the bacterial
suspension in desiccator attached to a vacuum system consisting
of a vacuum pump (Vacuubrand GMBH, Brackley, UK). Vacuum
was applied for 1 min at 100 mbar. The plants were then further
grown in a controlled environment room at 25 °C with 16/8 h
light/dark cycle.
Western blot detection of VRC01 expression in plant
leaves
Two leaf discs collected from transformed plants were homo-
genized with three volumes of 100 mM Tris (pH 8.0; Sigma),
150 mM NaCl (VWR International), 1 mM EDTA (VWR Interna-
tional, Leuven, Belgium) and 1 lM PMSF (Roche, Burgess Hill, UK)
using 3.175 mm chrome steel ball bearings and a Mixer Mill
MM400 (Retsch, Castleford, UK). 15 lL of total soluble extract
was resolved on NuPage 12% Bis-Tris gel (Life Technologies,
Paisley, UK) and transferred onto a nitrocellulose membrane. The
membrane was blocked with blocking buffer [50 mM Tris (pH
7.5), 150 mM NaCl, 1% Tween-20 (Sigma), 5% skimmed milk]
and incubated with 1 : 10 000 peroxidase-conjugated goat anti-
human kappa light chain antibody (Sigma, Gillingham, UK) to
detect the light chain or 1 : 10 000 peroxidase-conjugated
polyclonal goat anti-human IgG (Fc fragment) antiserum (Jackson
Immunoresearch, West Groove, CA) to detect the heavy chain.
Detection was performed using the ECL Prime system (Pierce,
Rockford, IL) and visualized using G:Box F3 (Syngene, Cambridge,
UK) or Amersham Hyperfilm ECL (GE Healthcare, Chalfont
St Giles, UK).
Immunoabsorbent assays (ELISA)
Five microgram per millilitre sheep anti-human IgG gamma heavy
chain Fc region (The Binding Site, Birmingham, UK) or 1 lg/mL
gp120 IIIB (NIH ARRRP) was coated for 2 h at 37 °C. The plates
were washed with three washes of wash buffer (water with
0.01% Tween-20). The plates were blocked with PBS with 5%
skimmed milk powder at 37 °C for 1 h. After three washes with
wash buffer, the antibody samples (as crude plant extracts or
pure protein) were incubated at 37 °C for 2 h (all dilutions were
done in blocking solution). The plates were washed three times
with wash buffer. A 1 : 1000 dilution of peroxidase-conjugate
goat anti-human kappa light chain (Sigma) was added for 1 h.
Bound antibodies were detected using TMB substrate solution
(3,3′,5,5′-tetramethylbenzidine (Sigma) in 25 mM citrate-50 mM
phosphate buffer, pH 5.0). The colour reaction was stopped by
addition of 2 M sulphuric acid, and the absorbance was deter-
mined at 450 nm using a Sunrise plate reader (Tecan, Theale,
UK). Titrations of known human IgG1 kappa (Sigma) were used
as standards to determine antibody concentration.
Protein purification
Vacuum infiltrated leaves were harvested at 6 days postinfection
(dpi) for transient plants or just before flowering for stable plants.
The leaves were extracted with three volumes of extraction buffer
(100 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA and 1 lM
PMSF). The clarified crude extracts were purified using a mixed
protein G-Sepharose/protein A-agarose (Sigma) column. The
column was washed with 10 column volumes (CV) of binding
buffer (20 mM sodium phosphate, pH 7.0) and the protein eluted
with elution buffer (0.1 M glycine-HCl, pH 2.7). The eluted
fraction was neutralized with 1 M Tris–HCl, pH 9.0 and then by
buffer-exchange diafiltration using Amicon Ultra-15 (Molecular
cut-off 100 kDa; Milipore, Ireland) or by dialysis using Slide-A-
Lyzer Cassettes (Molecular cut-off 3.5 kDa; Thermo Scientific,
USA) depending on the volume. Purified antibody concentration
was determined by direct ELISA using titrations of known human
IgG kappa (Sigma) as standards, reconfirmed with resolving
titrations of purified antibodies against known concentrations of
human IgG kappa on a NuPage 4%–12% Bis-Tris Coomassie gel
(Life Technologies) and either with A280 measurements using
NanoDrop 2000 (Thermo Scientific, USA) or with BCA protein
assay (Pierce, USA) using known concentration of bovine serum
albumin (BSA) as standards.
Glycopeptide analysis using LC-ESI-MS
Purified antibodies were reduced using 5 mM DTT in a 0.1 M
ammonium bicarbonate buffer at 56 °C for 45 min followed by
S-carbamidomethylation using 25 mM iodoacetamide in a 0.1 M
ammonium bicarbonate buffer at 25 °C for 30 min. After
precipitation using 80% acetone at 20 °C for 45 min, the
protein was digested with 0.2 lg trypsin in 0.1 M ammonium
bicarbonate buffer overnight at 37 °C. After deactivation of
trypsin at 96 °C for 6 min, the protein was digested with 0.2 lg
endoproteinase GluC in 0.1 M ammonium bicarbonate buffer
overnight at 37 °C. Glycopeptide analysis was performed using
liquid chromatography–electrospray ionization–mass spectrome-
try (LC-ESI-MS) as described previously (Pabst et al., 2012) with a
few modifications: the gradient was developed from 1% to 80%
acetonitrile over 60 min at a flow rate of 6 lL/min, using 0.3
formic acid buffered to pH 3.0 with ammonia as the aqueous
solvent. Peptide identification was performed with maXis 4G ETD
(Bruker, Germany) in positive ion mode (ion cooler transfer time:
100 ls, ion cooler prepulse storage time: 10 ls; low mass:
300.00 m/z, spectra rate: 1 Hz).
Surface plasmon resonance of antibody binding
The binding kinetics of plant- and HEK-cells-produced VRC01 to
HIV-1 gp120 IIIB were determined using a Protein A capture assay
(Floss et al., 2009). The assay was performed on a BIAcore X-100
instrument (GE healthcare, Chalfont St Giles, UK) at 25 °C with
buffer HBS-EP+ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM
EDTA and 0.05% surfactant P-20). Protein A (Sigma) was
immobilized onto a CM5 chip to 3988 response units (RUs)
with standard amine coupling. Purified VRC01 from plant or HEK
cells was diluted in HBS-EP+ buffer to yield a similar capture
level of 100 RUs. gp120 IIIB was injected at a concentration of
20 lg/mL for 3 min at the flow rate of 30 lL/min and allowed to
dissociate for another 7.5 min before regeneration with 10 mM
HCl for 1 min at the flow rate of 10 lL/min. Referenced and
blanked sensorgrams were fitted with BIAcore Evaluation
software using a 1 : 1 Langmuir model of binding. Each assay
was performed in triplicate. The relative activity (rela) of the plant-
derived VRC01 was calculated in relation to the HEK-cells-derived
VRC01 using the equation described by Floss et al. (2009) with
slight modifications: the gp120 binding response (Rt) was taken at
190 s after the start of injection.
HIV-1 neutralization assays
HIV-1 BaL neutralization assay was performed as described by Wei
et al. (2003) and Montefiori (2005). Briefly, 200 TCID50 of HIV-1
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BaL was incubated with dilutions of purified plant- or HEK-cells-
produced VRC01 for 1 h at 37 °C in a total volume of 100 lL.
Plant- and HEK-cells-produced VRC01 were titrated twofold seven
times in triplicate starting at 10 lg/mL. All dilutions were
performed in growth medium [DMEM with 10% foetal calf serum
(FCS), penicillin–streptomycin (100 units/mL and 100 lg/mL,
respectively) and 2 mM L-glutamine]. The mixture were then
added to 100 lL TZM-bl cells expressing CD4, CCR5 and firefly
luciferase gene under the control of HIV long-terminal repeat
sequence grown in growth medium preseeded at a concentration
of 5 9 105 cells/mL. Cells plus virus positive control and a cells
only background control were also added. After a 24-h incubation
in 37 °C, 5% CO2 followed by addition and incubation with lysis
buffer, the cell lysate was removed from each well and mixed in a
1 : 1 ratio with Bright Glo reagent (Promega, Southampton, UK) in
a 96-well white solid plates for luminescence measurements. The
percentage reduction in relative light units (RLU) was calculated
relative to the RLU of the ‘virus plus cells’ positive control. The
resulting curve was plotted and analysed in GraphPad Prism.
HIV-1 Env-pseudovirus neutralization assay measures reduction
of luciferase expression following a single round of pseudovirus
infection (Li et al., 2005). Stocks of Env-pseudovirus were
prepared by transfection of 293T/17 cells. Plant- and HEK-cells-
produced VRC01 were titrated fivefold seven times in duplicate
starting at 10 lg/mL. 200 TCID50 of pseudovirus was added with
the antibodies and incubated for 1 h at 37 °C. All other conditions
of the assay are as per those described with the HIV-1 BaL but with
a 48-h incubation time instead of 24 h. Both plant- and HEK-cells-
produced VRC01 were tested against 3 Clade B (SC422661.8,
PVO.4, AC10.0.29), 3 Clade C (Du156.12, ZM109.F.PB4,
ZM53M.PB12), 3 Clade A (3415.v1.c1, 3365.v2.c20, 0260.v5.c1)
and 1 Clade G (X1193_c1) pseudoviruses.
Statistical methods
All statistical analyses were performed using GraphPad Prism 6
software (GraphPad, San Diego) by one-way analysis of variance
(ANOVA) with the significance level set at P < 0.05. This is
followed by Tukey–Kramer post hoc analysis.
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